Skip to main content
. 2019 Jul 20;11(7):1025. doi: 10.3390/cancers11071025

Figure 6.

Figure 6

Phosphorylated NPM/B23 (Thr199) is capable of associating with CDK6. (a) ARK2 were treated with 2 μM palbociclib for 24 h (at the experimental conditions described in the Methods section). Whole-cell lysates were immunoprecipitated (IP) with an anti-CDK6 antibody (α-CDK6) and subsequently analyzed by immunoblotting with an anti-CDK6 antibody or an anti-NPM/B23 antibody. (b) ARK2 cells were transfected with the dephospho-mimetic NPM/B23 mutant (Thr199A) or the phospho-mimetic NPM/B23 mutant (Thr199D) for 24 h and immunoprecipitated (IP) with an anti-CDK6 antibody (α-CDK6). Subsequently, immunoblotting with an anti-CDK6 antibody or an anti-NPM/B23 antibody was performed. A control IgG antibody (α-IgG) was used for mock immunoprecipitation (HC, heavy chain; LC, light chain).